LabCorp

CND Life Sciences develops an evidence-based tool for confirming synucleinopathy diagnoses. Its Syn-One Test detects abnormal alpha-synuclein in cutaneous nerve fibers, aiding in diagnosing Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.

Founded in 2013, Olaris is dedicated to transforming disease diagnosis and treatment. Utilizing its CEREBRO platform, which integrates metabolomics and machine learning, the company discovers and develops precision diagnostics under its myOLARIS™ brand.

Percipio Health is a healthcare technology company that leverages artificial intelligence to enhance patient care. It provides a platform that integrates advanced computer vision software to monitor and assess patient health status. This technology enables clinicians and caregivers to maintain a comprehensive view of a patient's well-being and accurately identify medications. By offering AI-driven insights, Percipio Health empowers healthcare providers to make informed decisions, ultimately improving the quality of care delivered to patients.

Teal Health specializes in developing at-home cervical cancer screening devices, aiming to enhance convenience, privacy, and accessibility for women. Their FDA-approved platform includes a sampling device, virtual consultations with licensed providers, secure laboratory testing, an online results portal, and coordination of follow-up care.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

PreciseDx is a specialized company focused on cancer risk stratification, providing patient-specific risk assessments through the analysis of morphological features. By leveraging artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that enhance the understanding of a patient's risk profile and potential outcomes. This innovative approach allows clinical teams to gain valuable insights and actionable intelligence, facilitating more personalized treatment decisions. The company's expertise spans clinical modeling, patient phenotyping, image analysis, and the application of big data in real-world scenarios, ultimately aiming to improve patient outcomes and quality of life in cancer care and other diseases.

NOWDiagnostics, Inc. is a company based in Springdale, Arkansas, that specializes in the development and manufacturing of blood-based rapid diagnostic tests. Founded in 2013, the company offers innovative testing solutions that require only a single drop of blood, providing results within minutes. This approach empowers both patients and caregivers by enabling timely decision-making regarding healthcare. NOWDiagnostics' product line, ADEXUSDx, includes tests for various conditions such as pregnancy, cardiac events, and toxicology, all designed to be conducted in-home or in-clinic without the need for off-site laboratory processing. The company aims to reduce the waiting time for test results, enhancing the overall efficiency of medical diagnostics. NOWDiagnostics collaborates with strategic partners, including Zalgen Labs LLC, to expand its offerings in the diagnostic market.

Invitae is a genetic information company focused on integrating genetic insights into everyday medical practice to enhance healthcare quality for a large population. The company specializes in genetic diagnostics for hereditary disorders, offering a comprehensive service that consolidates multiple genetic tests into a single platform. Invitae's offerings include assessments for genes linked to hereditary cancer, neurological disorders, cardiovascular conditions, pediatric issues, metabolic disorders, and other hereditary ailments. By providing high-quality testing with quicker turnaround times and competitive pricing, Invitae aims to make genetic testing more accessible and effective for patients and healthcare providers alike.

Prolocor is a biotechnology company based in Philadelphia, PA. Founded in 2020, it specializes in developing diagnostic tests for cardiovascular diseases. The company aims to provide more precise methods and tools for assessing and managing risk in cardiovascular disease.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

HealthEC develops comprehensive technology solutions for exchanging healthcare information and managing population health globally. Its Population Health Management platform integrates critical components into a single platform, serving hospitals, providers, ACOs, health plans, and employers.

Adela specializes in developing innovative technologies for early detection of high-morbidity conditions like cancer through routine blood tests. Its proprietary platform efficiently captures and analyzes the methylome, focusing on highly informative regions to enhance diagnostic accuracy.

Vital Bio is focused on transforming lab testing to make healthcare more accessible and personalized. The company develops advanced diagnostic technologies that integrate devices, software, and services to support patients in monitoring their health and managing diseases. By bridging the gap between diagnosis and treatment, Vital Bio aims to empower patients and healthcare providers alike, promoting proactive care and reducing disparities in health outcomes. The company's innovative approach seeks to enhance the overall healthcare experience, ensuring that individuals have greater control over their health management.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Mercy BioAnalytics is a biotechnology company dedicated to improving and saving lives through early cancer detection. Founded in 2018, it has developed a proprietary platform that uses extracellular vesicles (EVs) in blood to detect stage I cancer.

Prolocor is a biotechnology company based in Philadelphia, PA. Founded in 2020, it specializes in developing diagnostic tests for cardiovascular diseases. The company aims to provide more precise methods and tools for assessing and managing risk in cardiovascular disease.

Epic Sciences is a diagnostics company focused on cancer management through blood-based tests that identify and characterize circulating tumor cells from a minimally invasive sample. Its platform profiles single-cell phenotype and genotype, including biomarker expression levels, subcellular localization, morphologic features, and genotypic metrics, and supports next-generation sequencing, FISH, and single-cell genomics to detect and characterize CTCs. The company develops tests such as the Oncotype DX AR-V7 Nucleus Detect for metastatic castration-resistant prostate cancer and offers biopharma solutions. It collaborates with biotechnology and pharmaceutical companies and cancer centers worldwide to provide real-time biopsy material and data to guide personalized medicine. By enabling analysis of rare cells before and after treatment, Epic Sciences aims to improve cancer management. The company was founded in 2008 and is headquartered in San Diego, California.

Getlabs is a digital health platform that facilitates at-home diagnostics. It enables healthcare organizations to send mobile phlebotomists to patients' homes nationwide for lab draws, vital checks, and advanced diagnostics, improving patient adherence and care gap closure.

PetDx is a San Diego-based molecular diagnostics company that specializes in the early detection of cancer in pets through innovative liquid biopsy technology. The company's main product, OncoK9, is a first-in-class multi-cancer early detection test that allows veterinarians to identify cancer in dogs using a simple blood draw. By utilizing advanced genomic analysis, including next-generation sequencing and proprietary bioinformatics algorithms, PetDx empowers veterinarians to enhance the care they provide to canine patients. The company's focus on non-invasive testing and customized assays positions it at the forefront of veterinary oncology, aiming to revolutionize how cancer is detected, characterized, and managed in pets.

Geneoscopy, LLC is a diagnostics company based in Saint Louis, Missouri, that specializes in non-invasive colorectal cancer screening and gastrointestinal disease management. Founded in 2015, Geneoscopy has developed a platform technology that utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the downstream effects of cancer-causing DNA mutations. The company's diagnostic test aims to improve compliance with colorectal cancer screening, facilitate early-stage detection of neoplasms, and ultimately reduce morbidity and mortality associated with the disease. Additionally, Geneoscopy is exploring other applications of its technology for various gastrointestinal conditions, aiming to provide reliable alternatives to traditional invasive procedures like colonoscopy.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

Biospectal is a remote patient monitoring and biosensing software company that has developed the OptiBP smartphone app, which allows users to measure and monitor blood pressure with medical-grade accuracy using their smartphones. The app utilizes the phone's built-in camera to optically measure blood flow from the user's fingertip, providing results in approximately 20 seconds, which is significantly faster than traditional blood pressure cuffs. Biospectal's proprietary algorithms interpret the captured data to deliver accurate blood pressure readings. The OptiBP app is currently available in public beta for Android users in several countries, including the United States, United Kingdom, France, Germany, Spain, and Switzerland. This innovative approach enables users to perform blood pressure measurements anytime and anywhere without the need for additional devices or accessories.

Advanced Animal Diagnostics, Inc. specializes in the research, development, and commercialization of on-farm diagnostic tools aimed at the early detection of subclinical mastitis in dairy cows. Founded in 2001 and based in Durham, North Carolina, the company offers innovative products such as the QScout Farm Lab, an analyzer system that detects infections before visible symptoms occur, and the QScout Milk Leukocyte Differential rapid test, which identifies and differentiates leukocytes in milk to facilitate early mastitis detection. Additionally, Advanced Animal Diagnostics provides the QuickSmear slide for animal research and the SCC+ System for timely mastitis diagnosis. The company's solutions focus on enhancing the management of disease states and improving the reproductive, nutritional, and overall health of production animals, serving veterinarians and livestock producers to promote healthier and more productive animal care.

Navigating Cancer, Inc., established in 2008 and headquartered in Seattle, Washington, operates a Web-based patient care portal designed specifically for cancer programs. This platform enables cancer survivors to receive, organize, and understand their medical information, track their health, and engage with healthcare professionals. It also offers educational resources on various types of cancer and chemotherapy treatments. The portal aims to simplify practice workflows for healthcare providers, facilitate patient-centered care, and improve overall outcomes by empowering patients through technology.

Sandstone Diagnostics, Inc. is a technology and healthcare company based in Pleasanton, California, that specializes in developing medical products and research tools focused on male fertility management. Founded in 2012, the company manufactures innovative devices such as the Torq ZDrive, which separates blood cells from liquid plasma at the point of collection, and the Torq Microvolume Rotor, a tool for remote blood sampling that facilitates comprehensive diagnostic testing. Additionally, Sandstone offers the Trak fertility system, which includes an engine, a disposable test plate, a sample collection cup, and a dropper, enabling men to monitor their sperm quality and take proactive steps toward improving their fertility. The accompanying Trak mobile application allows users to track their fertility data over time, identify potential fertility issues, and enhance their chances of conception. Sandstone Diagnostics aims to empower couples to manage their reproductive health in the comfort and privacy of their homes.

MC10, Inc. is a company that specializes in developing wearable medical sensors designed to collect clinical-grade biometric and physiological data. Founded in 2008 and based in Lexington, Massachusetts, the company offers a range of innovative products, including BioStamp nPoint for vital signs and activity monitoring, Kintinuum for orthopedic rehabilitation, WiSP for cardiac monitoring, and BioStampMD, a conformal sensor that gathers both objective and subjective health data. MC10 employs advanced flexible electronics technology, allowing its devices to bend and stretch with the body, ensuring comfort and ease of use. The company focuses on enhancing human capabilities and improving health insights through discreet, location-specific sensing that captures real-world data on muscle activation and movement, with applications extending across various sectors including sports, military, and energy.

OmniSeq is a molecular diagnostic laboratory based in Buffalo, New York, founded in 2015 as an innovation of Roswell Park Cancer Institute. The company specializes in providing actionable tumor-profiling information to physicians and their patients, aiming to identify the most suitable drug or clinical trial for each individual. OmniSeq offers New York State CLEP-approved assays, including the OmniSeq Comprehensive, a 144-gene next-generation sequencing assay that detects nearly all known genetic alterations tied to FDA-approved targeted therapies or genotype-directed clinical trials. The company also focuses on enhancing diagnostics for immuno-oncology therapy selection. By leveraging advanced molecular therapy technologies, including a proprietary algorithm that minimizes false positives, OmniSeq strives to improve access to cancer treatment options through precise and comprehensive molecular profiling.

The Recovery Platform is a medical enterprise dedicated to enhancing medication-assisted treatment (MAT) for substance use disorders. It provides a specialized platform that supports both physicians and patients in adhering to treatment protocols. The platform offers a comprehensive suite of tools designed to monitor patient compliance, track progress, and facilitate telehealth communication, as well as manage scheduling. By streamlining these processes, the Recovery Platform aids physicians in guiding their patients through the transition from opioid dependence to recovery, ensuring that compliance requirements are effectively managed while promoting best practices in treatment.

PAML is a healthcare solutions company with a focus in diagnostics. It proudly serve physicians, hospitals, members of the community, employers, and other allied health professionals.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

ClearPath Diagnostics is a pathologist-owned tissue pathology and cytology practice based in Syracuse, New York. Founded in 1975, the company specializes in providing a range of diagnostic services to healthcare providers and their patients across the United States. Its offerings include cytology and pathology services, as well as ancillary testing such as the Digene Hybrid Capture 2 for human papillomavirus (HPV), testing for gonorrhea and chlamydia, and immunohistochemistry. ClearPath also conducts frozen section analysis and provides in situ hybridization services to detect HPV and assess Her-2/neu gene amplification in breast cancer. Additionally, the company offers triple testing to identify vaginitis pathogens and Vysis UroVysion testing for the non-invasive evaluation of bladder cancer. Through its comprehensive diagnostic capabilities, ClearPath Diagnostics plays a vital role in enhancing patient care and treatment outcomes.

Sequenom, Inc. is a life sciences company that specializes in developing and commercializing molecular diagnostics testing services focused on women's health and oncology. The company offers a range of laboratory-developed tests (LDTs), including the MaterniT21 PLUS, a noninvasive prenatal test (NIPT) for detecting fetal chromosomal abnormalities, and the VisibiliT LDT, which assesses the relative amounts of chromosomal material in maternal blood samples. Sequenom also provides the MaterniT21 GENOME test for identifying genomic deletions or duplications, as well as the HerediT cystic fibrosis carrier screening test and the SensiGene fetal Rhesus D test. Additionally, the company offers microarray testing under the NextView brand and various carrier screening tests for genetic disorders under the HerediT brand. Founded in 1994 and headquartered in San Diego, California, Sequenom serves physicians and clinical laboratories, and it has established collaborations to enhance its genetic analysis capabilities. As of September 2016, Sequenom operates as a subsidiary of Laboratory Corporation of America Holdings.

Calif.-based laboratory firm

Ativa Medical Corporation is a medical device manufacturing company based in Saint Paul, Minnesota, founded in 2008. The company specializes in developing and commercializing point of care testing medical diagnostics products aimed at decentralized healthcare settings. Ativa Medical focuses on providing rapid diagnostic test results for critical hematology and clinical chemistry tests, utilizing advanced microfluidics technology. Its product offerings include analyzers and disposable test cards designed for trauma, pediatric, oncology, and geriatric patients. These products cater to various healthcare environments, including hospital departments, physician's offices, and remote healthcare clinics, enhancing the speed and accessibility of medical diagnostics.

Vivify Health Inc. is a digital health company based in Plano, Texas, founded in 2009. It operates a cloud-based, device-agnostic platform that facilitates home-based remote monitoring, connecting healthcare providers with patients through consumer electronics. This innovative platform aims to reduce hospital readmissions and overall healthcare costs by enabling automatic remote biometric data collection and delivering tailored care plans. Vivify Health also offers a range of personal health devices, including tablets, weight scales, and pulse oximeters, to enhance patient engagement and support virtual interactions between patients and healthcare professionals. The company is a subsidiary of Optum, Inc. and has established a strategic alliance with AT&T to further its mission of improving population health and patient satisfaction.

LipoScience is a Raleigh, North Carolina-based company specializing in personalized diagnostics through the use of nuclear magnetic resonance (NMR) technology. The company has developed the NMR LipoProfile test, its flagship diagnostic tool, which quantitatively measures low density lipoprotein particles (LDL-P) in blood samples. This test provides physicians and patients with critical information to tailor heart disease risk management effectively. Since its inception, LipoScience has seen significant adoption, with over 8 million NMR LipoProfile tests ordered to date.

YourBio Health specializes in innovative blood sampling technologies. Their flagship product, Seventh Sense On Vivo™ platform, enables safe and painless diagnostic testing using proprietary Touch Activated Phlebotomy™ (TAP™) technology. This single-step process can be integrated with various diagnostic assays for rapid results, improving patient experience and accessibility to critical healthcare information.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Flatiron Health, Inc. is a healthcare technology company dedicated to enhancing cancer research and patient care through advanced data integration and analytics. The firm develops OncologyCloud, a comprehensive platform that consolidates disparate healthcare information systems to provide insights into patient populations. This platform enables cancer care providers and life sciences companies to analyze treatment patterns, monitor adherence to clinical guidelines, and facilitate real-time patient matching to clinical trials. Additionally, Flatiron offers OncoCloud, a software solution for community oncology practices, and tools like Flatiron Assist and OncoEMR, which support clinical decision-making and compliance with oncology care models. Established in 2012 and headquartered in New York, Flatiron Health collaborates with over 280 community cancer practices, prominent academic research centers, and leading oncology companies, positioning itself as a key player in the oncology data landscape. The company operates as a subsidiary of Roche Holding AG.

Medtox Scientific operates a SAMHSA-certified drug testing laboratory, a CAP and CLIA-certified clinical laboratory, and an FDA-registered diagnostic division. The company provides comprehensive laboratory and diagnostic testing services, including medical drug monitoring, pain management, clinical toxicology, therapeutic drug monitoring, emergency toxicology, pediatric lead testing, forensic toxicology, and employment drug testing. Medtox Scientific is committed to delivering excellent customer service, ensuring efficient and effective operation of clients' testing programs. The company serves a diverse range of clients, including physician offices, corporations, clinics, health organizations, and government agencies, with a focus on building strong relationships and being responsive to client needs.

Clearstone Central Laboratories is the largest and most experienced private company.

Genzyme Genetics is an industry leading provider of reproductive and oncology testing in the United States.

DCL Medical Laboratories, Inc. is a provider of consultative laboratory testing solutions that specializes in anatomic and molecular pathology services. The company offers a range of testing options including diagnostic cytopathology, histopathology, and immunohistochemistry, along with a selection of antibodies for biomarker analysis. DCL Medical Laboratories also caters to clinical trials clients and provides reference testing services for hospitals and other laboratories, with a particular emphasis on women's health. Its testing portfolio includes ThinPrep Pap test processing and screening, HPV molecular testing, chlamydia and gonorrhea testing, and cystic fibrosis carrier screening for pre-conceptual and prenatal assessments. Serving the medical industry across the United States, DCL Medical Laboratories is dedicated to delivering high-quality diagnostic services tailored to meet the needs of its clients.

Monogram Biosciences is a leading developer of innovative products aimed at improving the treatment of infectious diseases, cancer, and other serious health conditions. The company specializes in molecular diagnostics and offers products such as Trofile, an assay that determines the tropism of a patient's HIV, facilitating personalized treatment options. Additionally, Monogram provides VeraTag technology, which enhances the development of targeted therapeutics. The company's solutions cater to healthcare providers and pharmaceutical companies, contributing to advancements in precision medicine and improving patient outcomes.

DSI Laboratories is an operator of a medical laboratory. it is a full-service medical reference and toxicology laboratory that offers clinical testing, histology, chemistry, cytology, microbiology, and molecular medicine testing services.

Litholink Corp is a clinical laboratory based in Chicago, Illinois, specializing in kidney disease management. The company offers 24-hour urine testing services aimed at kidney stone prevention, providing accurate test results and personalized treatment recommendations for patients. Litholink's national infrastructure supports seamless integration of its services, ensuring high levels of customer support and convenience for clients managing their laboratory needs.

Esoterix is a laboratory services company that specializes in high-quality scientific testing and exceptional customer service. The company offers a range of assays and profiles through its facilities located in the United States and Western Europe. In addition to laboratory testing for physician specialists, Esoterix provides clinical trial services and various support services, including information technology, managed care, and billing. Its commitment to innovation is evident in the development of new products designed to meet the evolving needs of the healthcare sector.

US Pathology Labs provider of anatomic pathology and oncology testing services with a focus on the outpatient market.

Dianon Systems delivers pathology testing services that combine academic expertise with personalized local care, covering dermatopathology, gastrointestinal pathology, and uropathology.

ViroMed Laboratories is an FDA-registered laboratory specializing in infectious disease testing. As part of LabCorp's Specialty Testing Group, the company offers a range of laboratory testing services tailored to support clients involved in human cells, tissues, and cellular and tissue-based products (HCT/Ps). Its services include testing for reproductive donors, tissue and eye banks, bone marrow and stem cells, cord blood, and blood. ViroMed Laboratories serves various sectors, including biotechnology, pharmaceuticals, medical devices, and integrated healthcare, ensuring comprehensive support for its diverse clientele.

Allied Clinical Laboratories, Inc. provides testing services to physicians, hospitals, and health care providers.

Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.